Increased risk of second primary cancers after a diagnosis of melanoma

Archives of Dermatology

Volumn 146, Issue 3, 2010, Pages 265-272

  Bradford, Porcia T ^a   Freedman, D Michal ^a   Goldstein, Alisa M ^a   Tucker, Margaret A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; SKIN NEOPLASMS; TIME FACTORS; UNITED STATES;

EID: 77949396613     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.2     Document Type: Article

References (57)

1. Freedman DM, Miller BA, Tucker MA. New malignancies following melanoma of skin, eye melanoma, and nonmelanoma eye cancer. In: Curtis RE, Freedman DM, Ron E, eds, et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006.
2. Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database. Version 6.5.2. http://www.seer.cancer.gov. Accessed September 29, 2009.
3. Johnson CH, Adamo M, eds. SEER Program Coding and Staging Manual. Bethesda, MD: National Cancer Institute; 2008.
4. US Census Bureau. Census 2000, Summary File 1, Table DP-1. http://www.census.gov/main/www/cen2000.html. Accessed August 24, 2009.
5. Percy C, Fritz A, Ries L, eds. Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Bethesda, MD: National Cancer Institute; 2001.
6. Swan J, Wingo P, Clive R, et al. Cancer surveillance in the US: can we have a national system? Cancer. 1998;83(7):1282-1291.
7. Begg CB. Methodological and statistical considerations in the study of multiple primary cancers. In: Neugut AI, Meadows AT, Robinson E, eds. Multiple Primary Cancers. Philadelphia, PA: Lippincott, Williams & Wilkins; 1999:13-26.
8. US Department of Health and Human Services. Code of Federal Regulations 45.46.101(b)(4). http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Accessed August 21, 2009.
9. Slingluff CL Jr, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery. 1993;113(3):330-339.
10. Pack GT, Scharnagel IM, Hillyer RA. Multiple primary melanoma. Cancer. 1952; 5(6):1110-1115.
11. Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6(1):1-45.
12. Beardmore GL, Davis NC. Multiple primary cutaneous melanomas. Arch Dermatol. 1975;111(5):603-609.
13. Veronesi U, Casinelli N, Bufalino R. Evaluation of the risk of multiple primaries in malignant cutaneous melanoma. Tumori. 1976;62(1):127-130.
14. Di Fronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999;6(7):705-711.
15. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma Res. 1995;5(6):433-438.
16. Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol. 1998;39(3):422-427.
17. Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol. 2006;142(4):433-438.
18. Savoia P, Quaglino P, Verrone A, Bernengo MG. Multiple primary melanomas: analysis of 49 cases. Melanoma Res. 1998;8(4):361-366.
19. Osterlind A, Olsen JH, Lynge E, Ewertz M. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985;68:361-388.
20. Tucker MA, Boice JD Jr, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:161-189.
21. Gutman M, Cnaan A, Inbar M, et al. Are malignant melanoma patients at higher risk for a second cancer? Cancer. 1991;68(3):660-665.
22. Swerdlow AJ, Storm HH, Sasieni PD. Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer. 1995;61(6):773-779.
23. Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer. 1996;73(2):255-259.
24. Wassberg C, Thorn M, Yuen J, Hakulinen T, Ringborg U. Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer. 1999;83 (3):314-317.
25. Levi F, La Vecchia C, Randimbison L, Te VC, Erler G. Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer. 1997;72(5):776-779.
26. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001;145(6):981-985.
27. Crocetti E, Carli P. Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur J Cancer Prev. 2004;13(1):33-37.
28. Hiatt RA, Krieger N, Sagebiel RW, Clark WH, Mihm MC Jr. Surveillance bias and the excess risk of malignant melanoma among employees of the Lawrence Livermore National Laboratory. Epidemiology. 1993;4(1):43-47.
29. Tucker MA, Fraser MC, Goldstein AM, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer. 2002; 94(12):3192-3209.
30. Buckel TB, Goldstein AM, Fraser MC, Rogers B, Tucker MA. Recent tanning use: a risk factor for melanoma. Arch Dermatol. 2006;142(4):485-488.
31. Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Multiple primary cutaneous melanomas. Cancer. 1992;70(7):1911-1916.
32. Brobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997; 4(1):19-23.
33. Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I-III malignant melanoma. Cancer. 1999;86(11):2252-2258.
34. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localized primary cutaneous melanoma. Lancet Oncol. 2005;6(8):608-621.
35. National Comprehensive Cancer Network. Melanoma: clinical practice guidelines in oncology. http://www.nccn.org. Accessed June 30, 2009.
36. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2208-2212.
37. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma, III: family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040-2059.
38. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma, I: common and atypical naevi. Eur J Cancer. 2005;41(1):28-44.
39. Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet. 2009;41(8):920-925.
40. Falchi M, Bataille V, Hayward NK, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet. 2009;41(8):915-919.
41. Fears TR, Bird CC, Guerry D IV, et al. Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res. 2002;62(14):3992-3996.
42. Lehtonen L, Eskola J, Vainio O, Lehtonen A. Changes in lymphocyte subsets and immune competence in very advanced age. J Gerontol. 1990;45(3):M108-M112.
43. Thivolet J, Nicolas JF. Skin ageing and immune competence. Br J Dermatol. 1990; 122(suppl 35):77-81.
44. Wanebo HJ, Cooper PH, Young DV, Harpole DH, Kaiser DL. Prognostic factors in head and neck melanoma: effect of lesion location. Cancer. 1988;62(4):831-837.
45. Ringborg U, Afzelius LE, Lagerlof B, et al. Cutaneous malignant melanoma of the head and neck: analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish Melanoma Study Group. Cancer. 1993; 71(3):751-758.
46. Baumert J, Schmidt M, Giehl KA, et al. Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype. Melanoma Res. 2009;19(1):24-30.
47. Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin's lymphoma. Cancer. 2001;91(4):874-880.
48. Landgren O, Pfeiffer RM, Stewart L, et al. Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer. 2007; 120(5):1099-1102.
49. Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27(6): 904-910.
50. Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1993;85(23):1932-1937.
51. Greene MH, Young TI, Clark WH Jr. Malignant melanoma in renal transplant patients. Lancet. 1981;1(8231):1196-1199.
52. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897-904.
53. Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer. 2004;111(5):792-794.
54. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene. 2003; 22(20):3042-3052.
55. Dunbar SF, Marks LB, Sober AJ, Rosenberg A, Suit HD. Connective tissue tumors in patients with cutaneous melanoma. J Am Acad Dermatol. 1994;31 (2, pt 1):216-219.
56. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol. 1997;24(5):504-514.
57. Inskip PD. Multiple primary tumors involving cancer of the brain and central nervous system as the first or subsequent cancer. Cancer. 2003;98(3):562-570.